[Federal Register Volume 73, Number 188 (Friday, September 26, 2008)]
[Notices]
[Pages 55859-55860]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-22611]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of Benztropinamine
Analogs To Treat Psychiatric and Neurological Disorders
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR Part 404.7(a)(1)(i), that the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive patent license to practice the inventions embodied in U.S.
Patent Application No. 60/689,746, filed June 10, 2005, now abandoned
[HHS Ref. No. E-089-2005/0-US-01]; PCT Patent Application No. PCT/
US2006/22401, filed June 7, 2006, now abandoned [HHS Ref. No. E-089-
2005/0-US-02]; U.S. Patent Application No. 11/917,036, filed December
10, 2007 [HHS Ref. No. E-089-2005/0-US-03]; European Patent Application
No. 06772641.4, filed December 7, 2007, which published as 1888064 on
February 20, 2008 [HHS Ref. No. E-089-2005/0-EP-04]; Australian Patent
Application No. 2006258035, filed November 30, 2007 [HHS Ref. No. E-
089-2005/0-AU-05]; Japanese Patent Application No. 2008-515947, filed
December 7, 2007 [HHS Ref. No. E-089-2005/0-JP-06]; and Canadian Patent
Application No. 2609577, filed November 23, 2007 [HHS Ref. No. E-089-
2005/0-CA-07], all of which are entitled ``Benztropinamine Analogs as
Dopamine Uptake Inhibitors'' (Inventors: Amy Newman and Jonathan Katz,
NIDA) to Shire LLC, having an office in at least Basingstoke, United
Kingdom. The patent rights in these inventions have been assigned to
the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the use of benztropinamine analogs,
[[Page 55860]]
specifically, compounds derived from Formula I, wherein B is NR \4\ and
wherein R \4\ is not CH3 (methyl group) to treat psychiatric
and neurological disorders.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
November 25, 2008 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Charlene A. Sydnor, Ph.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: (301) 435-4689; Facsimile: (301) 402-0220; e-
mail: [email protected].
SUPPLEMENTARY INFORMATION: This technology relates to the synthesis of
novel dopamine transport inhibitors and their use to treat mental
disorders. The inventors developed benztropinamine analogs by replacing
the benzhydrylether moiety of benztropine and its analogs with the
isosteric benzhydrylamine system in order to produce more stable
compounds with increased solubility and bioavailability for improved
therapeutic formulation and utility. These compounds have a high
affinity for the dopamine transporter and inhibit dopamine uptake, but
do not produce a significant stimulation of locomotor activity or
cocaine-like subjective effects in a drug discrimination model. These
compounds are useful for the treatment of mental disorders such as
conduct disorders, alcohol addiction, tobacco addiction, nicotine
addiction, drug addiction, sleep disorders, inhalation disorders,
Parkinsonism including Parkinson's disease, female and male orgasmic
disorders, female and male sexual arousal disorders, hypoactive sexual
desire disorders, and anxiety and/or depression disorders. These
compounds are also useful as imaging probes for detecting cocaine
binding sites, as well as monitoring or diagnosing Parkinson's disease.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part
404.7. The prospective exclusive license may be granted unless within
sixty (60) days from the date of this published notice, the NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR Part 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: September 17, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-22611 Filed 9-25-08; 8:45 am]
BILLING CODE 4140-01-P